Search Results - "Thomas, Sapana R."

A public genome-scale lentiviral expression library of human ORFs by Yang, Xiaoping, Boehm, Jesse S, Yang, Xinping, Salehi-Ashtiani, Kourosh, Hao, Tong, Shen, Yun, Lubonja, Rakela, Thomas, Sapana R, Alkan, Ozan, Bhimdi, Tashfeen, Green, Thomas M, Johannessen, Cory M, Silver, Serena J, Nguyen, Cindy, Murray, Ryan R, Hieronymus, Haley, Balcha, Dawit, Fan, Changyu, Lin, Chenwei, Ghamsari, Lila, Vidal, Marc, Hahn, William C, Hill, David E, Root, David E

“…Two sequence-verified, clonal, publicly available collections of human open reading frames are reported. One collection is in a lentiviral vector for…”
Get full text

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation by Emery, Caroline M, Hieronymus, Haley, Zhao, Jean J, Boehm, Jesse S, Golub, Todd, Yang, Xiaoping, Root, David E, Roberts, Thomas M, Hahn, William C, Hill, David E, Wilson, Christopher J, Weber, Barbara L, Garraway, Levi A, Johnson, Laura A, Kim, Sungjoon, Harris, Jennifer L, Kim, So Young, Vidal, Marc, Finan, Peter M, Myer, Vic E, Sellers, William R, Barretina, Jordi, Alkan, Ozan, Thomas, Sapana R, Wardwell, Leslie, Cogdill, Alexandria P, Dummer, Reinhard, Schlegel, Robert, Stransky, Nicolas, Flaherty, Keith T, Wargo, Jennifer A, Murray, Ryan R, Johannessen, Cory M, Salehi-Ashtiani, Kourosh, Caponigro, Giordano

“…Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have…”
Get full text

PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling by Moody, S E, Schinzel, A C, Singh, S, Izzo, F, Strickland, M R, Luo, L, Thomas, S R, Boehm, J S, Kim, S Y, Wang, Z C, Hahn, W C

“…Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive breast cancer leads to improved survival, but resistance is a common clinical…”
Get full text

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling by Shrestha, Y, Schafer, E J, Boehm, J S, Thomas, S R, He, F, Du, J, Wang, S, Barretina, J, Weir, B A, Zhao, J J, Polyak, K, Golub, T R, Beroukhim, R, Hahn, W C

“…Activating mutations in the RAS family or BRAF frequently occur in many types of human cancers but are rarely detected in breast tumors. However, activation of…”
Get full text

COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation by Johannessen, Cory M., Boehm, Jesse S., Kim, So Young, Thomas, Sapana R., Wardwell, Leslie, Johnson, Laura A., Emery, Caroline M., Stransky, Nicolas, Cogdill, Alexandria P., Barretina, Jordi, Caponigro, Giordano, Hieronymus, Haley, Murray, Ryan R., Salehi-Ashtiani, Kourosh, Hill, David E., Vidal, Marc, Zhao, Jean J., Yang, Xiaoping, Alkan, Ozan, Kim, Sungjoon, Harris, Jennifer L., Wilson, Christopher J., Myer, Vic E., Finan, Peter M., Root, David E., Roberts, Thomas M., Golub, Todd, Flaherty, Keith T., Dummer, Reinhard, Weber, Barbara, Sellers, William R., Schlegel, Robert, Wargo, Jennifer A., Hahn, William C., Garraway, Levi A.

“…Oncogenic mutations in the serine/threonine kinase B-RAF are found in 50–70% of malignant melanomas 1 . Pre-clinical studies have demonstrated that the B-RAF…”
Get full text